Investors · CSE: PHRM · OTCQB: PHRRF
We are a specialty pharma company focused on 3D-printed medicines.
The opportunity in front of us
1 · The target: large markets and a national network
US$295BPeptide therapeutics by 2033, up from US$141B
US$1.2TPersonalized medicine by 2033, up from US$567B
US$59BMedical countermeasures by 2030, up from US$41B
10,000+Potential network sites in North America (management estimate)
2 · The path: catalysts and what each unlocks
Q4 2026Network launch; first 503A products; designation applicationsProduct revenue begins
Q1 2027Ketamine dissolvable tablet launch; pre-IND meetingTelehealth sales; first ANDA payments expected
Next 12 monthsUp to 50 placements; preparedness demoProductive nodes and recurring revenue
2027–28Licences, readiness contracts, new programsUltra-rare, psychedelic, discontinued and short-supply medicines
Q4 2028Rare pediatric NDA (target)Path to approval and orphan exclusivity
BeyondFirst FDA approval of a PharmaTher printed medicinePotential voucher; reported sales US$100–155M
3 · The moat: how the pieces lock together
Exclusive rightsSole North American CraftMake™ distributor
Productive nodesEach can earn repeat revenue and extend every product’s reach
Our formulations & dataPharmaTher owns its formulations, data and filings
Switching costsChanging systems means validating formulations again
A moat that widens with every nodeEvery new node adds reach, capacity and data, and makes switching away harder
Non-dilutive upside: ketamine ANDA >US$25M potential · 49% of Sairiyo Therapeutics
Market sizes are third-party estimates of total markets, not PharmaTher revenue. Nodes require site qualification; readiness contracts are prospective. Voucher values are from 2024–25 sale press releases; award and value are not assured. Targets and timelines are internal estimates and forward-looking. Forward-looking statements